Every 8-K that 20/20 Biolabs Inc (AIDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIDX filings page.
20/20 Biolabs, Inc. (NASDAQ: AIDX) furnished an investor webinar presentation outlining its multi-cancer early detection strategy, regulatory engagement, and commercial progress for its OneTest platform. The materials emphasize integration of serial biomarker testing, machine learning, and anti-inflammatory lifestyle interventions, and discuss potential positioning for future Medicare coverage of multi-cancer early detection blood tests beginning in 2028.
The company reports that Q2 2026 produced its best quarterly cancer testing revenue to date, with a 47% year-over-year increase, driven by 29 orders from new occupational health and clinical accounts and expanding firefighter screening programs in Maryland and Vermont. 20/20 Biolabs also describes preliminary, non-binding discussions with senior FDA personnel about evidence generation and potential regulatory pathways, and outlines planned next steps including formal interactions such as informational meetings, possible Breakthrough Device designation requests, and Q-Submissions, while cautioning that requirements, timing, and outcomes may differ materially from current expectations.
20/20 Biolabs, Inc. (AIDX) reported the results of its August 18, 2026 annual stockholders meeting held via webcast. Stockholders of record on June 22, 2026, holding 12,251,198 common shares, were entitled to vote, and 4,256,837 shares were represented, constituting a quorum.
Six directors were elected, each receiving roughly 2.65–2.73 million votes for and about 156–176 thousand votes withheld, with 1,433,721 broker non-votes on each director. Stockholders ratified dbbmckennon as independent registered public accounting firm for 2026 with 4,105,584 votes for, 132,421 against, and 18,832 abstentions. They also approved the 2026 Equity Incentive Plan with 2,183,335 votes for, 573,931 against, 65,850 abstentions, and 1,433,721 broker non-votes, and approved the ability to adjourn the meeting if needed, by 3,037,106 votes for, 1,132,166 against, and 87,565 abstentions. A charter amendment proposal did not receive sufficient votes and the meeting was adjourned on that item to September 16, 2026.
20/20 BioLabs, Inc. reported strong top-line improvement for the quarter ended June 30, 2026. Revenue rose 36.5% to $730,571 from $535,060, driven by OneTest™ multi-cancer early detection blood tests, which increased 47.1% to $697,034 and represented 95.3% of total revenue.
Gross profit grew 86.6% to $304,727, with gross margin expanding to 41.7% from 30.5%, reflecting favorable mix and better fixed-cost absorption. However, operating expenses increased to $1.55 million from $1.01 million, largely due to Nasdaq listing costs and product development spend, leading to a quarterly net loss of $1.51 million versus $0.84 million a year earlier.
For the first half of 2026, revenue was essentially flat at $1.08 million, while net loss widened to $3.68 million. Liquidity improved meaningfully: cash rose to $4.55 million at June 30, 2026 from $1.03 million at year-end 2025, primarily from $6.0 million of Series E preferred financing, and all convertible note debt was eliminated. Stockholders’ equity turned positive at $1.62 million from a slight deficit.
20/20 Biolabs, Inc. outlines materials used in an August 5, 2026 investor webinar describing U.S. legislation creating the Multi-Cancer Early Detection Screening Coverage Act, which gives CMS authority to reimburse multi-cancer blood tests beginning in 2028. Management believes its OneTest multi-cancer assay could be positioned for Medicare reimbursement if it obtains FDA authorization and meets CMS clinical appropriateness criteria.
The presentation contrasts OneTest’s 12‑marker protein and inflammation panel, serial testing three times per year, and machine‑learning “velocity” algorithms with ctDNA approaches such as Grail’s Galleri, noting that Galleri’s randomized NHS‑Galleri trial of over 142,000 participants missed its primary endpoint and has a $949 list price. Exact Sciences’ Cologuard revenue ramp from $2M to $266M after Medicare coverage is used only as a contextual analogy.
Business updates include preliminary, unaudited indications that Q2 2026 produced the company’s best quarterly cancer testing revenue to date, 29 orders from new accounts, a Maryland firefighter screening program covering 18 departments and more than 1,400 participants, and selection for a Vermont program to screen up to 4,500 firefighters. The company describes a three‑month Giant Food pilot for its longevity test, a roll‑up M&A strategy targeting companies with $2–$8 million in annualized revenue, and hypothetical revenue projections that imply a 5% royalty pool of about $100 million over five years to be shared pro‑rata with “data investors,” all expressly conditioned on achieving regulatory and reimbursement milestones.
20/20 Biolabs, Inc. entered a standstill agreement with Streeterville Capital related to its previously arranged offering of up to $40,000,000 of Series E convertible preferred stock at $1,000 per share. For 120 days from July 16, 2026, Streeterville agrees not to convert Series E preferred shares into common stock unless the trading price is at least 10% greater than the Nasdaq “Minimum Price”, with the standstill ending upon any breach of the agreement or an Event of Default.
The company also received a Nasdaq notice of non-compliance with the $1.00 minimum bid price requirement after its shares closed below $1.00 for 30 consecutive business days from June 3, 2026 to July 16, 2026. 20/20 Biolabs has until January 13, 2027 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day period or eventual delisting if compliance is not restored.
20/20 Biolabs, Inc. used this report to share an investor presentation on its OneTest multi‑cancer early detection strategy, focused on potential future Medicare reimbursement. The company highlights the new Multi‑Cancer Early Detection Screening Coverage Act, which creates a pathway for Medicare coverage of multi‑cancer blood tests starting in 2028 for FDA‑authorized products deemed appropriate by CMS.
The presentation contrasts protein‑based OneTest with ctDNA competitors and describes a serial biomarker‑tracking model that uses 12 cancer and inflammation markers, velocity algorithms, and an anti‑inflammatory diet program. It cites modeled early‑stage sensitivity improvements with more frequent testing and real‑world data from over 35,000 U.S. firefighters by the end of 2026. Management also outlines an M&A strategy targeting health‑and‑wellness businesses with $2–$8 million in annual revenue and includes illustrative revenue projections and a 5% royalty pool for “data investors,” all explicitly labeled as hypothetical and contingent on obtaining FDA authorization and Medicare reimbursement.
20/20 Biolabs, Inc. reported that its Board of Directors approved an amendment to the company’s Amended and Restated Bylaws on May 19, 2026. The change lowers the shareholder quorum requirement for stockholder meetings from a majority of shares outstanding to one-third of shares outstanding.
This adjustment makes it easier for the company to reach a valid quorum and conduct official business at stockholder meetings, which can be important when investor participation is limited. The full text of Amendment No. 1 to the bylaws is filed as an exhibit to this report.
20/20 BioLabs reported first quarter 2026 results showing lower revenue and a wider loss but a much stronger cash position. Revenue for the three months ended March 31, 2026 was $353,375, down from $553,820 a year earlier, with gross margin at 17.8%.
Net loss widened to $2,174,836 from $764,577, reflecting higher sales, general and administrative costs tied to becoming a Nasdaq-listed public company, non-cash losses on convertible notes, and warrant remeasurement. Cash and cash equivalents increased to $4,219,099 from $1,025,987 at year-end, helped by a $5,000,000 Series E preferred stock private placement and new convertible notes.
The company highlighted state-funded firefighter cancer screening programs expected to drive revenue growth beginning in Q2 2026, a distribution agreement with Evexia Diagnostics, a CKD-focused license with ROKIT Healthcare, and the commercial launch of its OneTest™ for Longevity chronic disease risk test.
20/20 Biolabs, Inc. entered a global amendment with Streeterville Capital on April 23, 2026 that significantly reprices existing equity warrants. The amendment reduces the exercise price of three previously issued Streeterville warrants to $2.25 per share, subject to standard anti-dilution adjustments.
These warrants were originally issued alongside secured convertible promissory notes of $295,000 and $275,000, each paired with a warrant to purchase 62,500 common shares at $8.00, and a financing in which Streeterville bought 5,000 shares of series E convertible preferred stock and a warrant to purchase 3,502,627 common shares at $11.42 per share for $5,000,000. The amendment gives the company a right to terminate within 90 days on at least two trading days’ written notice, during which period Streeterville may exercise the warrants at the reduced price.
20/20 BioLabs, Inc. reported full year 2025 results with revenue of $2.0 million, up 17% from 2024. Gross profit rose to $0.6 million and gross margin expanded to 29.6% from 20.6%, helped by a higher mix of BioCheck and CLIAX revenue.
Operating expenses fell to $3.9 million from $6.0 million, improving the net loss to $3.7 million from $5.6 million. Cash was $1.0 million at year-end 2025, and in February 2026 the company closed a $5.0 million tranche under a preferred purchase agreement that could total up to $40 million. Management highlights a state-funded firefighter cancer screening program, deferred revenue of about $0.5 million, the launch of OneTest for Longevity and a recent Nasdaq listing as positioning the company for 2026 growth.